Figure 4.

Cumulative incidence rates of malignancies (excluding nonmelanoma skin cancer) to week 144. CZP, certolizumab pegol; PBO, placebo; PY, patient‐years; Q2W, every 2 weeks; TEAE, treatment‐emergent adverse event. ^aPatients on CZP 200 mg Q2W received a loading dose of CZP 400 mg at weeks 0, 2 and 4. Error bars correspond to 95% confidence intervals.